173 related articles for article (PubMed ID: 38311852)
1. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice.
Shin DH; Jiang H; Gillard AG; Kim D; Fan X; Singh SK; Nguyen TT; Sohoni SS; Lopez-Rivas AR; Parthasarathy A; Ene CI; Gumin J; Lang FF; Alonso MM; Gomez-Manzano C; Fueyo J
Mol Ther; 2024 Mar; 32(3):722-733. PubMed ID: 38311852
[TBL] [Abstract][Full Text] [Related]
2. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus.
Phillips LM; Li S; Gumin J; Daou M; Ledbetter D; Yang J; Singh S; Parker Kerrigan BC; Hossain A; Yuan Y; Gomez-Manzano C; Fueyo J; Lang FF
Neuro Oncol; 2021 Nov; 23(11):1911-1921. PubMed ID: 34059921
[TBL] [Abstract][Full Text] [Related]
3. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models.
Martínez-Vélez N; Garcia-Moure M; Marigil M; González-Huarriz M; Puigdelloses M; Gallego Pérez-Larraya J; Zalacaín M; Marrodán L; Varela-Guruceaga M; Laspidea V; Aristu JJ; Ramos LI; Tejada-Solís S; Díez-Valle R; Jones C; Mackay A; Martínez-Climent JA; García-Barchino MJ; Raabe E; Monje M; Becher OJ; Junier MP; El-Habr EA; Chneiweiss H; Aldave G; Jiang H; Fueyo J; Patiño-García A; Gomez-Manzano C; Alonso MM
Nat Commun; 2019 May; 10(1):2235. PubMed ID: 31138805
[TBL] [Abstract][Full Text] [Related]
4. The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.
Kleijn A; Kloezeman J; Treffers-Westerlaken E; Fulci G; Leenstra S; Dirven C; Debets R; Lamfers M
PLoS One; 2014; 9(5):e97495. PubMed ID: 24866126
[TBL] [Abstract][Full Text] [Related]
5. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death.
Alonso MM; Jiang H; Yokoyama T; Xu J; Bekele NB; Lang FF; Kondo S; Gomez-Manzano C; Fueyo J
Mol Ther; 2008 Mar; 16(3):487-93. PubMed ID: 18253154
[TBL] [Abstract][Full Text] [Related]
6. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.
Ulasov IV; Zhu ZB; Tyler MA; Han Y; Rivera AA; Khramtsov A; Curiel DT; Lesniak MS
Hum Gene Ther; 2007 Jul; 18(7):589-602. PubMed ID: 17630837
[TBL] [Abstract][Full Text] [Related]
7. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model.
Jiang H; Clise-Dwyer K; Ruisaard KE; Fan X; Tian W; Gumin J; Lamfers ML; Kleijn A; Lang FF; Yung WK; Vence LM; Gomez-Manzano C; Fueyo J
PLoS One; 2014; 9(5):e97407. PubMed ID: 24827739
[TBL] [Abstract][Full Text] [Related]
8. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
9. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway.
Fueyo J; Alemany R; Gomez-Manzano C; Fuller GN; Khan A; Conrad CA; Liu TJ; Jiang H; Lemoine MG; Suzuki K; Sawaya R; Curiel DT; Yung WK; Lang FF
J Natl Cancer Inst; 2003 May; 95(9):652-60. PubMed ID: 12734316
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic virotherapy for the treatment of pediatric brainstem gliomas.
Gállego Pérez-Larraya J; García-Moure M; Alonso MM
Rev Neurol (Paris); 2023 Jun; 179(5):475-480. PubMed ID: 37061388
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas.
Jiang H; Gomez-Manzano C; Lang FF; Alemany R; Fueyo J
Curr Gene Ther; 2009 Oct; 9(5):422-7. PubMed ID: 19860656
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic adenovirus Delta-24-RGD induces a widespread glioma proteotype remodeling during autophagy.
González-Morales A; Zabaleta A; García-Moure M; Alonso MM; Fernández-Irigoyen J; Santamaría E
J Proteomics; 2019 Mar; 194():168-178. PubMed ID: 30503830
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11.
Mato-Berciano A; Morgado S; Maliandi MV; Farrera-Sal M; Gimenez-Alejandre M; Ginestà MM; Moreno R; Torres-Manjon S; Moreno P; Arias-Badia M; Rojas LA; Capellà G; Alemany R; Cascallo M; Bazan-Peregrino M
J Control Release; 2021 Apr; 332():517-528. PubMed ID: 33675877
[TBL] [Abstract][Full Text] [Related]
14. Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.
Lang FF; Conrad C; Gomez-Manzano C; Yung WKA; Sawaya R; Weinberg JS; Prabhu SS; Rao G; Fuller GN; Aldape KD; Gumin J; Vence LM; Wistuba I; Rodriguez-Canales J; Villalobos PA; Dirven CMF; Tejada S; Valle RD; Alonso MM; Ewald B; Peterkin JJ; Tufaro F; Fueyo J
J Clin Oncol; 2018 May; 36(14):1419-1427. PubMed ID: 29432077
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic concentrations of anti-epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24-RGD in malignant glioma.
de Jonge J; Berghauser Pont LM; Idema S; Kloezeman JJ; Noske D; Dirven CM; Lamfers ML
J Gene Med; 2013; 15(3-4):134-41. PubMed ID: 23606319
[TBL] [Abstract][Full Text] [Related]
16. Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.
Hemminki O; Diaconu I; Cerullo V; Pesonen SK; Kanerva A; Joensuu T; Kairemo K; Laasonen L; Partanen K; Kangasniemi L; Lieber A; Pesonen S; Hemminki A
Mol Ther; 2012 Sep; 20(9):1821-30. PubMed ID: 22871667
[TBL] [Abstract][Full Text] [Related]
17. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
Pesonen S; Diaconu I; Cerullo V; Escutenaire S; Raki M; Kangasniemi L; Nokisalmi P; Dotti G; Guse K; Laasonen L; Partanen K; Karli E; Haavisto E; Oksanen M; Karioja-Kallio A; Hannuksela P; Holm SL; Kauppinen S; Joensuu T; Kanerva A; Hemminki A
Int J Cancer; 2012 Apr; 130(8):1937-47. PubMed ID: 21630267
[TBL] [Abstract][Full Text] [Related]
18. An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment.
Kostova Y; Mantwill K; Holm PS; Anton M
Cancer Gene Ther; 2015 Jan; 22(1):30-43. PubMed ID: 25501992
[TBL] [Abstract][Full Text] [Related]
19. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models.
Geletneky K; Kiprianova I; Ayache A; Koch R; Herrero Y Calle M; Deleu L; Sommer C; Thomas N; Rommelaere J; Schlehofer JR
Neuro Oncol; 2010 Aug; 12(8):804-14. PubMed ID: 20299703
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic adenovirus based on serotype 3.
Hemminki O; Bauerschmitz G; Hemmi S; Lavilla-Alonso S; Diaconu I; Guse K; Koski A; Desmond RA; Lappalainen M; Kanerva A; Cerullo V; Pesonen S; Hemminki A
Cancer Gene Ther; 2011 Apr; 18(4):288-96. PubMed ID: 21183947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
